OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

      Sotorasib, a specific and irreversible KRASG12C inhibitor, has demonstrated clinical activity as monotherapy in KRAS p.G12C-mutated solid tumors. Genomic alterations of receptor tyrosine kinase (RTK) were identified as a common putative resistance mechanism to sotorasib in the CodeBreaK100 Ph1/2 trial, highlighting the potential role for combining sotorasib with upstream RTK signaling inhibitors. In mouse xenograft models, combining sotorasib with a SHP2 inhibitor (SHP2i) impaired RTK signaling to RAS and enhanced anti-tumor efficacy. Herein, we report the first safety and efficacy data for sotorasib combined with RMC-4630, a small molecule SHP2i.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect